

# Jurgen B Bulitta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1126019/publications.pdf>

Version: 2024-02-01

160  
papers

6,139  
citations

61984

43  
h-index

95266

68  
g-index

174  
all docs

174  
docs citations

174  
times ranked

5778  
citing authors

#	ARTICLE	IF	CITATIONS
1	Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 356-363.	3.0	12
2	Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable <i>Pseudomonas aeruginosa</i> via a Dynamic Biofilm Model and Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0220321.	3.2	4
3	Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model. <i>Antibiotics</i> , 2022, 11, 101.	3.7	4
4	Synthesis and Structure-Activity Relationship of Thioacetamide-Triazoles against <i>Escherichia coli</i> . <i>Molecules</i> , 2022, 27, 1518.	3.8	3
5	Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers. <i>AAPS Journal</i> , 2022, 24, 9.	4.4	0
6	Research priorities towards precision antibiotic therapy to improve patient care. <i>Lancet Microbe</i> , The, 2022, 3, e795-e802.	7.3	17
7	Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines. <i>Microorganisms</i> , 2021, 9, 307.	3.6	7
8	Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1000-1020.	4.7	10
9	Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1104-1115.	4.7	16
10	Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?. <i>AAPS Journal</i> , 2021, 23, 48.	4.4	13
11	Emergence of Resistance to Ceftazidime-Avibactam in a <i>Pseudomonas aeruginosa</i> Isolate Producing Derepressed <i>bla</i> <sub>PDC</sub> in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	8
12	Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0069221.	3.2	9
13	Informing and Validating Translational Mechanism-Based Models for Antibiotics by Experimental and Computational Approaches. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1426-1428.	4.7	3
14	First Penicillin-Binding Protein Occupancy Patterns for 15 $\beta$ -Lactams and $\beta$ -Lactamase Inhibitors in <i>Mycobacterium abscessus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	16
15	FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	11
16	Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2622-2632.	3.0	39
17	Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five $\beta$ -Lactams Simultaneously in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Enterobacter cloacae</i> . <i>MBio</i> , 2020, 11, .	4.1	17
18	Four Decades of $\beta$ -Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 143-156.	3.5	15

#	ARTICLE	IF	CITATIONS
19	Cascade Impactor Equivalence Testing: Comparison of the Performance of the Modified Chi-Square Ratio Statistic (mCSRS) with the Original CSRS and EMA's Average Bioequivalence Approach. <i>AAPS PharmSciTech</i> , 2019, 20, 249.	3.3	5
20	Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics. <i>Pharmaceutics</i> , 2019, 11, 323.	4.5	4
21	Natural history of <i>Acinetobacter baumannii</i> infection in mice. <i>PLoS ONE</i> , 2019, 14, e0219824.	2.5	26
22	Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable <i>Pseudomonas Aeruginosa</i> Strains via Mechanism-Based Modelling. <i>Pharmaceutics</i> , 2019, 11, 470.	4.5	4
23	Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding. <i>Pharmaceutics</i> , 2019, 11, 286.	4.5	10
24	Comparable Efficacy and Better Safety of Double $\beta$ -Lactam Combination Therapy versus $\beta$ -Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	24
25	Generating Robust and Informative Nonclinical <i>In Vitro</i> and <i>In Vivo</i> Bacterial Infection Model Efficacy Data To Support Translation to Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	124
26	Characterization of Hypermutator <i>Pseudomonas aeruginosa</i> Isolates from Patients with Cystic Fibrosis in Australia. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	30
27	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	21
28	Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics. <i>International Journal of Pharmaceutics</i> , 2019, 556, 276-286.	5.2	13
29	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against <i>Pseudomonas aeruginosa</i> for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	21
30	Determination of the small RNA GcvB regulon in the Gram-negative bacterial pathogen <i>Pasteurella multocida</i> and identification of the GcvB seed binding region. <i>Rna</i> , 2018, 24, 704-720.	3.5	26
31	Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable <i>Pseudomonas aeruginosa</i> via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	31
32	Combating Carbapenem-Resistant <i>Acinetobacter baumannii</i> by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	10
33	Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD). <i>Drug Delivery and Translational Research</i> , 2018, 8, 729-739.	5.8	11
34	Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 957-965.	4.7	43
35	Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> and <i>Escherichia coli</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 69-76.	1.8	4
36	First Penicillin-Binding Protein Occupancy Patterns of $\beta$ -Lactams and $\beta$ -Lactamase Inhibitors in <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	48

#	ARTICLE	IF	CITATIONS
37	Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	29
38	Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved in situ Absorption Method in Rats. <i>Pharmaceutics</i> , 2018, 10, 174.	4.5	5
39	Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	19
40	First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 416-428.	4.0	6
41	Meropenem Combined with Ciprofloxacin Combats Hypermutable <i>Pseudomonas aeruginosa</i> from Respiratory Infections of Cystic Fibrosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	26
42	Prolonged and continuous antibacterial and anti-biofilm activities of thin films embedded with gentamicin-loaded mesoporous silica nanoparticles. <i>Applied Nanoscience (Switzerland)</i> , 2018, 8, 1471-1482.	3.1	13
43	Influence of <i>rhlR</i> and <i>lasR</i> on Polymyxin Pharmacodynamics in <i>Pseudomonas aeruginosa</i> and Implications for Quorum Sensing Inhibition with Azithromycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	13
44	High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant <i>Acinetobacter baumannii</i> in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	60
45	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	34
46	The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. <i>Intensive Care Medicine</i> , 2017, 43, 1021-1032.	8.2	100
47	Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 107, 32-44.	4.0	4
48	Polymyxin-resistant, carbapenem-resistant <i>Acinetobacter baumannii</i> is eradicated by a triple combination of agents that lack individual activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1415-1420.	3.0	44
49	Aminoglycosides against carbapenem-resistant <i>Enterobacteriaceae</i> in the critically ill: the pitfalls of aminoglycoside susceptibility. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 519-526.	4.4	44
50	Pharmacodynamics of dose-escalated "front-loading" polymyxin B regimens against polymyxin-resistant <i>mcr-1</i> -harbouring <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2297-2303.	3.0	14
51	Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in a Murine Thigh Infection Model by Using Humanized Dosing Schemes. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	18
52	Aminoglycoside Concentrations Required for Synergy with Carbapenems against <i>Pseudomonas aeruginosa</i> Determined via Mechanistic Studies and Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	31
53	Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac. <i>AAPS Journal</i> , 2017, 19, 1814-1825.	4.4	2
54	Polymyxin Combinations Combat <i>Escherichia coli</i> Harboring <i>mcr-1</i> and <i>bla</i> <sub>NDM-5</sub> : Preparation for a Postantibiotic Era. <i>MBio</i> , 2017, 8, .	4.1	50

#	ARTICLE	IF	CITATIONS
55	Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical <i>Pseudomonas aeruginosa</i> Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	27
56	Development of a Physiologically Relevant Population Pharmacokinetic <i>in Vitro</i> – <i>in Vivo</i> Correlation Approach for Designing Extended-Release Oral Dosage Formulation. <i>Molecular Pharmaceutics</i> , 2017, 14, 53-65.	4.6	24
57	Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	12
58	High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 153-165.	3.0	36
59	Effect of Sipjeondaebotang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling. <i>Molecules</i> , 2017, 22, 1488.	3.8	2
60	Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine. <i>Molecules</i> , 2017, 22, 1515.	3.8	4
61	Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling. <i>PLoS Computational Biology</i> , 2016, 12, e1004782.	3.2	50
62	Defining the Active Fraction of Daptomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach. <i>PLoS ONE</i> , 2016, 11, e0156131.	2.5	5
63	Polymyxin Resistance in <i>Acinetobacter baumannii</i> : Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens. <i>Scientific Reports</i> , 2016, 6, 26233.	3.3	82
64	Translational Modeling of Antibacterial Agents. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 371-402.	0.6	0
65	Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2870-2880.	3.2	18
66	Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3913-3920.	3.2	43
67	Colistin and Polymyxin B Dosage Regimens against <i>Acinetobacter baumannii</i> : Differences in Activity and the Emergence of Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3921-3933.	3.2	66
68	Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2234-2240.	3.0	10
69	Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3157-3167.	3.0	26
70	Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 719-724.	2.5	14
71	Polymyxin B in combination with doripenem against heteroresistant <i>Acinetobacter baumannii</i> : pharmacodynamics of new dosing strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3148-3156.	3.0	36
72	Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant <i>Acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 331-336.	2.5	28

#	ARTICLE	IF	CITATIONS
73	Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats. <i>BMC Pharmacology &amp; Toxicology</i> , 2016, 17, 35.	2.4	2
74	Effect of different renal function on antibacterial effects of piperacillin against <i>Pseudomonas aeruginosa</i> evaluated via the hollow-fibre infection model and mechanism-based modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2509-2520.	3.0	38
75	Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab <sup>2</sup> Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity. <i>Molecular Pharmaceutics</i> , 2016, 13, 1229-1241.	4.6	25
76	Novel Rate-Area-Shape Modeling Approach To Quantify Bacterial Killing and Regrowth for In Vitro Static Time-Kill Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 381-388.	3.2	13
77	Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. <i>Infectious Diseases and Therapy</i> , 2015, 4, 391-415.	4.0	45
78	Stability and controlled antibiotic release from thin films embedded with antibiotic loaded mesoporous silica nanoparticles. <i>RSC Advances</i> , 2015, 5, 107839-107846.	3.6	11
79	Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 818-826.	3.0	20
80	PEGylation Does Not Significantly Change the Initial Intravenous or Subcutaneous Pharmacokinetics or Lymphatic Exposure of Trastuzumab in Rats but Increases Plasma Clearance after Subcutaneous Administration. <i>Molecular Pharmaceutics</i> , 2015, 12, 794-809.	4.6	34
81	Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use. <i>Pharmacotherapy</i> , 2015, 35, 34-42.	2.6	52
82	Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2286-2298.	3.2	52
83	Controlling antibiotic release from mesoporous silica nano drug carriers via self-assembled polyelectrolyte coating. <i>Journal of Materials Science: Materials in Medicine</i> , 2015, 26, 117.	3.6	29
84	Colistin and doripenem combinations against <i>Pseudomonas aeruginosa</i> : profiling the time course of synergistic killing and prevention of resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1434-1442.	3.0	60
85	Population data analysis of dissolution time profiles: Assessment of physicochemical properties of the drug, drug particles and the pharmaceutical formulation. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 78, 245-254.	4.0	7
86	Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans. <i>AAPS Journal</i> , 2015, 17, 1210-1223.	4.4	20
87	Emergence of Polymyxin B Resistance Influences Pathogenicity in <i>Pseudomonas aeruginosa</i> Mutators. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4343-4346.	3.2	5
88	Two Mechanisms of Killing of <i>Pseudomonas aeruginosa</i> by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2315-2327.	3.2	76
89	Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6241-6247.	3.2	19
90	Evaluation of enrofloxacin use in koalas ( <i>Peromyscus colarctos cinereus</i> ) via population pharmacokinetics and Monte Carlo simulation. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2014, 37, 301-311.	1.3	14



#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats. <i>Xenobiotica</i> , 2014, 44, 913-925.	1.1	20
92	Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2508-2516.	3.0	29
93	Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 92, 177-182.	2.8	36
94	Quantitative Determination of Absorption and First-Pass Metabolism of Apicidin, a Potent Histone Deacetylase Inhibitor. <i>Drug Metabolism and Disposition</i> , 2014, 42, 974-982.	3.3	9
95	The Lymphatic System Plays a Major Role in the Intravenous and Subcutaneous Pharmacokinetics of Trastuzumab in Rats. <i>Molecular Pharmaceutics</i> , 2014, 11, 496-504.	4.6	49
96	New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1381-1388.	3.2	30
97	Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2334-2343.	3.2	96
98	The Impact of Lymphatic Transport on the Systemic Disposition of Lipophilic Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2395-2408.	3.3	25
99	Combination therapy for carbapenem-resistant Gram-negative bacteria. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 1333-1353.	4.4	112
100	PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. <i>Journal of Controlled Release</i> , 2013, 172, 128-136.	9.9	74
101	Synergistic Activity of Colistin and Rifampin Combination against Multidrug-Resistant <i>Acinetobacter baumannii</i> in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3738-3745.	3.2	94
102	Population Pharmacokinetics of Fusidic Acid: Rationale for Front-Loaded Dosing Regimens Due to Autoinhibition of Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 498-507.	3.2	40
103	Mechanism-Based Model of Parasite Growth and Dihydroartemisinin Pharmacodynamics in Murine Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 508-516.	3.2	20
104	Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2343-2351.	3.2	68
105	Resistance Emergence Mechanism and Mechanism of Resistance Suppression by Tobramycin for Cefepime for <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 231-242.	3.2	52
106	Impact of Two-Component Regulatory Systems PhoP-PhoQ and PmrA-PmrB on Colistin Pharmacodynamics in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3453-3456.	3.2	25
107	Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3712-3719.	3.2	29
108	Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2182-2190.	3.0	33

#	ARTICLE	IF	CITATIONS
109	Evaluation of Once-Daily Vancomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 682-686.	3.2	33
110	Population Pharmacokinetics of Piperacillin at Two Dose Levels: Influence of Nonlinear Pharmacokinetics on the Pharmacodynamic Profile. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5715-5723.	3.2	30
111	The Combination of Colistin and Doripenem Is Synergistic against <i>Klebsiella pneumoniae</i> at Multiple Inocula and Suppresses Colistin Resistance in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5103-5112.	3.2	85
112	Powder Strength Distributions for Understanding De-agglomeration of Lactose Powders. <i>Pharmaceutical Research</i> , 2012, 29, 2926-2935.	3.5	22
113	Synergistic Killing of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> at Multiple Inocula by Colistin Combined with Doripenem in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5685-5695.	3.2	107
114	Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> at Multiple Inocula. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5134-5142.	3.2	109
115	Evaluation of the pharmacokinetics and pharmacodynamics of fusidic acid against <i>Staphylococcus aureus</i> and <i>Streptococcus pyogenes</i> using <i>in vitro</i> infection models: implications for dose selection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 101-111.	1.8	12
116	Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT. <i>AAPS Journal</i> , 2011, 13, 201-211.	4.4	111
117	Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models. <i>AAPS Journal</i> , 2011, 13, 212-226.	4.4	83
118	Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 465-475.	2.3	7
119	Effect of Half-Life on the Pharmacodynamic Index of Zanamivir against Influenza Virus Delineated by a Mathematical Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1747-1753.	3.2	27
120	Relevance of Pharmacokinetic and Pharmacodynamic Modeling to Clinical Care of Critically Ill Patients. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 2044-2061.	1.6	47
121	Application of Pharmacokinetic-Pharmacodynamic Modeling and the Justification of a Novel Fusidic Acid Dosing Regimen: Raising Lazarus From the Dead. <i>Clinical Infectious Diseases</i> , 2011, 52, S513-S519.	5.8	43
122	Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 583-592.	3.2	107
123	Population Pharmacokinetics of a Novel Histone Deacetylase Inhibitor, Cyclo{(2S)-2-Amino-8-[(Aminocarbonyl)Hydrazono]Decanoyl-1-Tryptophyl-Isoleucyl-(2R)-2-Piperidinecarbonyl} (SD-2007), and Its Metabolic Conversion to Apicidin after Intravenous Injection and Oral Administration in Rats. <i>Chemotherapy</i> , 2011, 57, 259-267.	1.6	1
124	Pharmacokinetics of Ertapenem in Colorectal Tissue. <i>Chemotherapy</i> , 2011, 57, 437-448.	1.6	6
125	Population Pharmacokinetics and Penetration into Prostatic, Seminal, and Vaginal Fluid for Ciprofloxacin, Levofloxacin, and Their Combination. <i>Chemotherapy</i> , 2011, 57, 402-416.	1.6	21
126	Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2927-2936.	3.2	10



#	ARTICLE	IF	CITATIONS
127	Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing. <i>Pharmacotherapy</i> , 2010, 30, 1279-1291.	2.6	340
128	Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 167-178.	2.4	41
129	Nonlinear pharmacokinetics of piperacillin in healthy volunteers – implications for optimal dosage regimens. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 682-693.	2.4	30
130	Pharmacokinetic/Pharmacodynamic Investigation of Colistin against <i>Pseudomonas aeruginosa</i> Using an <i>In Vitro</i> Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3783-3789.	3.2	150
131	Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1275-1282.	3.2	48
132	Assessment of Bisphenol a Exposure in Korean Pregnant Women by Physiologically Based Pharmacokinetic Modeling. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2010, 73, 1586-1598.	2.3	20
133	Attenuation of Colistin Bactericidal Activity by High Inoculum of <i>Pseudomonas aeruginosa</i> Characterized by a New Mechanism-Based Population Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2051-2062.	3.2	119
134	Bone Penetration of Amoxicillin and Clavulanic Acid Evaluated by Population Pharmacokinetics and Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2569-2578.	3.2	30
135	Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA): Implications for Dosing in MRSA Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3894-3901.	3.2	49
136	Modeling the Autoinhibition of Clarithromycin Metabolism during Repeated Oral Administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2892-2901.	3.2	20
137	Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 46-56.	3.2	88
138	New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3462-3471.	3.2	19
139	Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2074-2081.	3.2	32
140	Competitive Inhibition of Renal Tubular Secretion of Gemifloxacin by Probenecid. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3902-3907.	3.2	19
141	Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1049-1063.	2.3	43
142	Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1035-1048.	2.3	26
143	The time course of drug effects. <i>Pharmaceutical Statistics</i> , 2009, 8, 176-185.	1.3	15
144	Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 130-141.	1.8	17

#	ARTICLE	IF	CITATIONS
145	Penetration of Antibacterials into Bone. <i>Clinical Pharmacokinetics</i> , 2009, 48, 89-124.	3.5	252
146	Physiologically Based Pharmacokinetics of Zearalenone. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2009, 72, 1395-1405.	2.3	30
147	Disposition, Oral Bioavailability, and Tissue Distribution of Zearalenone in Rats at Various Dose Levels. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2009, 72, 1406-1411.	2.3	38
148	Pharmacokinetics of 1,4-Butanediol in Rats: Bioactivation to $\hat{1}^3$ -Hydroxybutyric Acid, Interaction with Ethanol, and Oral Bioavailability. <i>AAPS Journal</i> , 2008, 10, 56-69.	4.4	13
149	Inhibition of flucloxacillin tubular renal secretion by piperacillin. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 648-659.	2.4	34
150	Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation To Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1945-1951.	3.2	23
151	Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2497-2507.	3.2	108
152	Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3304-3310.	3.2	138
153	Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3290-3297.	3.2	63
154	Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 987-993.	3.0	96
155	Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1881-1889.	3.2	87
156	Ertapenem Pharmacokinetics and Impact on Intestinal Microflora, in Comparison to Those of Ceftriaxone, after Multiple Dosing in Male and Female Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3765-3772.	3.2	100
157	Vom Farbstoff zum Rezeptor: Paul Ehrlich und die Chemie. <i>Nachrichten Aus Der Chemie</i> , 2004, 52, 777-782.	0.0	9
158	ABT-773: Pharmacokinetics and Interactions with Ranitidine and Sucralfate. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1129-1131.	3.2	14
159	Effects of grapefruit juice on the pharmacokinetics of sildenafil. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 21-29.	4.7	77
160	Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 262-274.	4.7	34